Skip to main content

For information on the Change Healthcare cyber response:



For Providers - Get information on temporary funding assistance:

Find out about our temporary funding assistance program for those affected by payment services disruptions.

Drug Pipeline Insights Report

4 new drugs to watch this year

Breakthrough treatments for menopause, Alzheimer's and hemophilia are coming.

By Sumit Dutta, MD, Chief Medical Officer at Optum Rx­ | Published: Jan. 2023

Slowing Alzheimer's decline and a potential cure for hemophilia A

Optum Rx drug pipeline insights report Winter 2023

Welcome to the first issue of Drugs to Watch for 2023

In this Drug Pipeline Insights Report, we feature:

  • Two new treatments for Alzheimer's disease: lecanemab and donanemab
  • RoctavianTM (valoctocogene roxaparvovec), a first-in-class gene therapy for hemophilia A 
  • A first-in-class, non-hormonal treatment for menopause associated-vasomotor symptoms (VMS): fezolinetant

New hope for hemophilia

Roctavian could reduce or eliminate the need for costly clotting factor replacement therapy in some patients. Last fall, we reviewed etranacogene dezaparvovec for hemophilia B, which is now approved with the brand name Hemgenix®

Download now

Don't want to read the full report? Download the brief summary.

View Summary

Related content

3 new drugs to watch this fall

As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision this fall.

4 key forces shaping the future of pharmacy

These emerging trends will help define the road ahead.

Fighting fraud in pharmacy

Explore emerging trends and strategies to combat schemes.